NOL10 and cancer: This study provides new insights into the possible implication of circ-SMARCA5, circ-NOL10, circ-LDLRAD3, circ-RHOT1 in CRC progression, where they are expressed differentially in CRC patients as well as non-cancer patients (UC, polyp, and piles).